Erkekte Alt Üriner Sistem Semptomları

Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn, 2002. 21: 167.

Martin SA, Haren MT, Marshall VR, et al. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol, 2011. 29: 179.

Gacci M, Corona G, Vignozzi L, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int, 2015. 115: 24.

Gacci M, Corona G, Sebastianelli A, et al. Male Lower Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-analysis. Eur Urol, 2016. 70: 788.

Chapple CR, Osman NI, Birder L, et al. Terminology report from the International Continence Society (ICS) Working Group on Underactive Bladder (UAB). Neurourol Urodyn, 2018. 37: 2928.

Vaughan CP, Johnson TM 2nd, Goode PS, et al. Military exposure and urinary incontinence among American men. J Urol, 2014. 191: 125.

Bright E, Cotterill N, Drake M, et al. Developing and validating the International Consultation on Incontinence Questionnaire bladder diary. Eur Urol, 2014. 66: 294.

Bohnen AM, Groeneveld FP, Bosch JL. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol, 2007. 51: 1645.

Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update.

Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet, 2003. 361: 1359.

Elsherbini T, Bouhadana D, Sadri I, et al. The impact of 5-ARI on perioperative and functional outcomes of GreenLight PVP: an analysis of the Global GreenLight Group database. Can J Urol, 2023. 30: 11473.

Wagg A, Nitti VW, Kelleher C, et al. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin, 2016. 32: 621.

Staskin D, Frankel J, Varano S, et al. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. J Urol, 2020. 204: 316.

Nagasubramanian S, John NT, Antonisamy B, Nagasubramanian, S., et al. Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial. BJU Int, 2020. 125: 718.

Lenfant L, Pinar U, Roupret M, et al. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. J Urol, 2023. 209: 314.

Hashim H, Worthington J, Abrams P, et al. Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial. Lancet, 2020. 396: 50.

Arcaniolo D, Manfredi C, Veccia A et al. Bipolar endoscopic enucleation versus bipolar transurethral resection of the prostate: an ESUT systematic review and cumulative analysis. World J Urol, 2020. 38: 1177.

Bhandarkar A, Patel D. Comparison of Holmium Laser Enucleation of the Prostate with Bipolar Plasmakinetic Enucleation of the Prostate: A Randomized, Prospective Controlled Trial at Midterm Follow-Up. J Endourol. 2022 Dec;36(12):1567.

Hartung FO, Kowalewski KF, von Hardenberg J, et al. Holmium Versus Thulium Laser Enucleation of the Prostate: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus, 2022. 8: 545.

Bozzini G, Berti L, Maltagliati M, et al. Thulium: YAG vs continuous-wave thulium fiber laser enucleation of the prostate: do potential advantages of thulium fiber lasers translate into relevant clinical differences? World J Urol, 2023. 41: 143.

Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn, 2002. 21: 167.

Martin SA, Haren MT, Marshall VR, et al. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol, 2011. 29: 179.

Gacci M, Corona G, Vignozzi L, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int, 2015. 115: 24.

Gacci M, Corona G, Sebastianelli A, et al. Male Lower Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-analysis. Eur Urol, 2016. 70: 788.

Chapple CR, Osman NI, Birder L, et al. Terminology report from the International Continence Society (ICS) Working Group on Underactive Bladder (UAB). Neurourol Urodyn, 2018. 37: 2928.

Vaughan CP, Johnson TM 2nd, Goode PS, et al. Military exposure and urinary incontinence among American men. J Urol, 2014. 191: 125.

Bright E, Cotterill N, Drake M, et al. Developing and validating the International Consultation on Incontinence Questionnaire bladder diary. Eur Urol, 2014. 66: 294.

Bohnen AM, Groeneveld FP, Bosch JL. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol, 2007. 51: 1645.

Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update.

Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet, 2003. 361: 1359.

Elsherbini T, Bouhadana D, Sadri I, et al. The impact of 5-ARI on perioperative and functional outcomes of GreenLight PVP: an analysis of the Global GreenLight Group database. Can J Urol, 2023. 30: 11473.

Wagg A, Nitti VW, Kelleher C, et al. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin, 2016. 32: 621.

Staskin D, Frankel J, Varano S, et al. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. J Urol, 2020. 204: 316.

Nagasubramanian S, John NT, Antonisamy B, Nagasubramanian, S., et al. Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial. BJU Int, 2020. 125: 718.

Lenfant L, Pinar U, Roupret M, et al. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. J Urol, 2023. 209: 314.

Hashim H, Worthington J, Abrams P, et al. Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial. Lancet, 2020. 396: 50.

Arcaniolo D, Manfredi C, Veccia A et al. Bipolar endoscopic enucleation versus bipolar transurethral resection of the prostate: an ESUT systematic review and cumulative analysis. World J Urol, 2020. 38: 1177.

Bhandarkar A, Patel D. Comparison of Holmium Laser Enucleation of the Prostate with Bipolar Plasmakinetic Enucleation of the Prostate: A Randomized, Prospective Controlled Trial at Midterm Follow-Up. J Endourol. 2022 Dec;36(12):1567.

Hartung FO, Kowalewski KF, von Hardenberg J, et al. Holmium Versus Thulium Laser Enucleation of the Prostate: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus, 2022. 8: 545.

Bozzini G, Berti L, Maltagliati M, et al. Thulium: YAG vs continuous-wave thulium fiber laser enucleation of the prostate: do potential advantages of thulium fiber lasers translate into relevant clinical differences? World J Urol, 2023. 41: 143.